8-K: Citius Oncology Launches LYMPHIR for CTCL Treatment

Citius Oncology announces the U.S. commercial launch of LYMPHIR, an FDA-approved IL-2 receptor-directed fusion protein for relapsed or refractory Stage I-III cutaneous T-cell lymphoma, targeting a $400M+ market.

Summary

• Citius Oncology, Inc. (CTOR) has commercially launched LYMPHIR (denileukin diftitox-cxdl) in the U.S. on December 1, 2025.
• LYMPHIR is an FDA-approved IL-2 receptor-directed fusion protein indicated for adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.
• The U.S. addressable market for LYMPHIR is estimated to exceed $400 million and is projected to grow.
• Clinical data from Pivotal Study 302 demonstrated an Objective Response Rate (ORR) of 36.2%, with 9% achieving complete response and 27% achieving partial response.
• 84% of evaluable patients experienced a reduction in skin tumor burden, with 48.4% achieving a 50% reduction.
• The median time to achieve an objective response was 1.4 months, and the median duration of disease control was 6.5 months.
• LYMPHIR is now available nationwide through specialty distributors (Cencora, Cardinal Health, McKesson) and has been assigned a permanent J-code (J9161) effective April 1, 2025.
• It has been included in the National Comprehensive Cancer Network (NCCN) Guidelines for CTCL with a Category 2A recommendation.
• Citius Oncology holds exclusive rights to LYMPHIR in all global markets except India, Japan, and certain parts of Asia, and has signed a distribution agreement with Integris Pharma S.A. for 12 European markets.
• Citius Oncology is a majority-owned (~79%) subsidiary of Citius Pharmaceuticals (CTXR) and operates with a shared management services agreement.

Sentiment

Score: 7

Explanation: The commercial launch of LYMPHIR is a significant positive milestone for Citius Oncology, addressing an underserved market with a novel, FDA-approved therapy. The strong clinical data, robust commercial infrastructure, and potential for label expansion and international growth are highly favorable. However, the serious safety warnings, particularly the Boxed Warning for Capillary Leak Syndrome, and the explicit mention of the need for additional funding temper the overall sentiment, indicating inherent risks in a biopharmaceutical company launch.

Positives

• Commercial launch of LYMPHIR, the first marketed product for Citius Oncology, addressing an unmet medical need in CTCL.
• LYMPHIR is the only FDA-approved IL-2 receptor-directed therapy for CTCL, offering a novel mechanism of action.
• Strong clinical efficacy demonstrated with an Objective Response Rate (ORR) of 36.2% and 84% of evaluable patients experiencing a reduction in skin tumor burden.
• Rapid response time with a median of 1.4 months to achieve an objective response and meaningful activity on severe pruritus.
• Durable response with a median of 6.5 months of disease control among responders, and 52% of responders maintaining response for at least 6 months.
• Estimated U.S. addressable market of over $400 million, with potential for further growth through international expansion and new indications.
• Robust commercial infrastructure in place, including nationwide distribution, a permanent J-code (J9161 effective April 1, 2025), and NCCN Guidelines inclusion (Category 2A).
• Strong intellectual property protection including 12 years of BLA exclusivity, Orphan Drug Exclusivity, proprietary manufacturing process, and two pending patents for combination therapy.
• Potential for label expansion into Peripheral T-cell lymphoma (PTCL) and ongoing investigator-initiated trials exploring combination therapies with KEYTRUDA in solid tumors (27% ORR, 33% Clinical Benefit Rate in preliminary data) and CAR T therapies in B-cell lymphomas.
• No evidence of cumulative toxicity observed in clinical trials, differentiating it from some existing CTCL treatments.

Negatives

• LYMPHIR carries a Boxed Warning for Capillary Leak Syndrome (CLS), which occurred in 27% of patients in clinical trials, including 8% Grade 3 and one (0.8%) fatal occurrence.
• Other serious adverse reactions include visual impairment (9% overall, 1% Grade 2), infusion-related reactions (69% overall, 3.4% Grade 3), and hepatotoxicity (elevated ALT in 70% with 22% Grade 3; elevated AST in 64% with 9% Grade 3).
• LYMPHIR can cause embryo-fetal toxicity and may compromise male fertility, requiring contraception for females of reproductive potential and advising against breastfeeding.
• The company relies on third-party logistics providers, distributors, and specialty pharmacies, which introduces supply chain risks.
• The need for substantial additional funds to fund operations for at least the next 12 months is highlighted as a risk factor.

Risks

• Need for substantial additional funds and ability to raise additional money to fund operations for at least the next 12 months as a going concern.
• Ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream.
• Physician and patient acceptance of LYMPHIR in a competitive treatment landscape.
• Reliance on third-party logistics providers, distributors, and specialty pharmacies to support commercial operations.
• Ability to educate providers and payers, secure adequate reimbursement, and maintain uninterrupted product supply.
• Post-marketing requirements and ongoing regulatory compliance related to LYMPHIR.
• Ability to secure strategic partnerships and expand international access to LYMPHIR.
• Ability to use the latest technology to support commercialization efforts.
• The estimated markets for LYMPHIR and product candidates and their acceptance.
• Risks relating to the results of research and development activities, including existing and new pipeline assets.
• Ability to procure cGMP commercial-scale supply.
• Ability to obtain, perform under, and maintain financing and strategic agreements and relationships.
• Ability to maintain Nasdaq's continued listing standards.
• Market and other conditions.
• Risks related to growth strategy.
• Patent and intellectual property matters.
• Ability to identify, acquire, close, and integrate product candidates and companies successfully and on a timely basis.
• Government regulation.
• Capillary Leak Syndrome (CLS), including life-threatening or fatal reactions, can occur.
• Serious visual impairment, including changes in visual acuity and color vision, can occur.
• Serious infusion-related reactions can occur.
• Hepatotoxicity can occur.
• Embryo-fetal toxicity and potential fetal harm if administered to a pregnant woman.
• Potential compromise of male fertility.

Future Outlook

Citius Oncology anticipates significant growth opportunities for LYMPHIR beyond its initial CTCL indication, including potential label expansion into Peripheral T-cell lymphoma (PTCL) and ongoing investigator-initiated trials exploring its use in combination with PD-1 inhibitors (KEYTRUDA) for solid tumors and CAR T therapies for B-cell lymphomas, with preliminary data from these studies expected in Q1 2026. The company also plans to expand international market access through strategic partnerships, building on its initial agreement for 12 European markets.

Management Comments

• "LYMPHIR is an important new treatment option for the CTCL community, and its launch marks the beginning of a new chapter for Citius Oncology." Leonard Mazur, Chairman & CEO.
• "With a median time to response of 1.4 months in the Phase 3 trial, we believe LYMPHIR may offer rapid skin relief, among other benefits, to patients suffering from severe and debilitating itching common with the disease." Leonard Mazur, Chairman & CEO.
• "This is our first marketed product and the culmination of years of development work and commercial preparation. LYMPHIR addresses a clear clinical need in a disease with limited treatment options." Leonard Mazur, Chairman & CEO.
• "Ultimately, we expect LYMPHIR to be a meaningful addition to the treatment paradigm for CTCL and a value-driving catalyst for Citius Oncology shareholders." Leonard Mazur, Chairman & CEO.
• "We estimate that LYMPHIR is entering a growing U.S. market valued at over $400 million, with further upside opportunities through international market access and potential expanded indications in the future." Leonard Mazur, Chairman & CEO.
• "Our focus now is on execution to ensure that LYMPHIR reaches the patients who need it." Leonard Mazur, Chairman & CEO.
• "LYMPHIR is an important new tool in the fight against CTCL. It is the only FDA-approved systemic therapy for CTCL in more than seven years." Dr. Myron Czuczman, EVP & Chief Medical Officer.
• "LYMPHIRs direct tumoricidal activity and transient T-regulatory cell depletion offer a powerful new approach to disease control without cumulative toxicity. As such, LYMPHIRs clinical profile makes it a compelling treatment option for physicians and patients facing the burden of relapsed or refractory CTCL." Dr. Myron Czuczman, EVP & Chief Medical Officer.

Industry Context

The launch of LYMPHIR introduces a novel, FDA-approved IL-2 receptor-directed therapy into the underserved market for cutaneous T-cell lymphoma (CTCL), an orphan cancer with limited systemic treatment options and no curative therapies beyond allogeneic stem cell transplantation for a small fraction of patients. LYMPHIR's unique mechanism of action and lack of cumulative toxicity position it favorably against existing treatments, which often have limitations such as biomarker requirements, peripheral neuropathy, or bone marrow toxicity. The market for CTCL treatments has seen no new systemic therapies approved in over seven years, suggesting a significant opportunity for LYMPHIR to capture market share and potentially expand the overall market size, aligning with historical trends where new therapeutics drive market growth.

Comparison to Industry Standards

• LYMPHIR is the only FDA-approved IL-2 receptor-directed therapy for CTCL, distinguishing it from other systemic treatments.
• Unlike some existing therapies that require specific biomarkers (e.g., CD30+), LYMPHIR has a broad label and does not require a biomarker.
• LYMPHIR's clinical profile, including rapid response (median 1.4 months) and significant reduction in skin tumor burden (84.4% of evaluable patients), addresses a key quality-of-life issue (pruritus) that current non-curative CTCL treatments often struggle with.
• The absence of cumulative toxicity for LYMPHIR contrasts with some older CTCL treatments where cumulative bone marrow toxicity can limit use.
• The estimated $400M+ U.S. addressable market for CTCL is considered underserved, as no new systemic therapy has been approved since 2018, indicating a significant gap that LYMPHIR aims to fill.
• Preliminary data from an investigator-initiated trial combining LYMPHIR with KEYTRUDA (a PD-1 inhibitor from Merck & Co., Inc.) in solid tumors showed a 27% ORR and 33% Clinical Benefit Rate in 15 evaluable patients, suggesting potential competitive efficacy in immuno-oncology combinations.

Related Party Transactions

• Citius Oncology is a majority-owned (~79%) subsidiary of Citius Pharmaceuticals (NASDAQ: CTXR).
• Citius Oncology has a shared management services agreement with Citius Pharmaceuticals for operational efficiency.

Stakeholder Impact

• Shareholders: The commercial launch of LYMPHIR is expected to be a value-driving catalyst, potentially increasing revenue and market share, but also carries risks associated with commercialization and the need for future funding.
• Patients (CTCL): LYMPHIR offers a new, FDA-approved systemic treatment option for relapsed or refractory Stage I-III CTCL patients, potentially providing rapid skin relief and disease control without cumulative toxicity, addressing a high unmet medical need.
• Healthcare Providers: LYMPHIR provides a novel IL-2 receptor-directed therapy for CTCL, supported by clinical data, NCCN guidelines, and comprehensive access/education tools.
• Payers: The permanent J-code (J9161) effective April 1, 2025, and reimbursement support programs aim to streamline claims processing and facilitate access.
• Employees: The successful commercialization and potential expansion could lead to job stability and growth opportunities within Citius Oncology.

Next Steps

• Execution of commercial strategy to ensure LYMPHIR reaches patients in the U.S.
• Educating providers and payers, securing adequate reimbursement, and maintaining uninterrupted product supply.
• Ongoing regulatory compliance related to LYMPHIR.
• Securing strategic partnerships to expand international access to LYMPHIR beyond the initial 12 European markets.
• Anticipated Phase 1 study data for LYMPHIR in combination with KEYTRUDA in solid tumors in Q1 2026.
• Anticipated preliminary study results for LYMPHIR in combination with CAR T therapies in B-cell lymphomas in Q1 2026.
• Potential label expansion for LYMPHIR in Peripheral T-cell lymphoma (PTCL).

Key Dates

Recommendation

The commercial launch of LYMPHIR is a significant positive event for Citius Oncology, marking its first marketed product in an underserved orphan cancer market with substantial revenue potential. The strong clinical data, novel mechanism, and strategic commercial rollout are compelling. However, the stock is likely to have already priced in the FDA approval and subsequent launch. The explicit disclosure of serious safety warnings, particularly the Boxed Warning for Capillary Leak Syndrome, and the stated need for substantial additional funds to cover operations for the next 12 months introduce material risks. While there's upside potential from label expansion and international markets, the immediate focus should be on successful commercial execution and managing safety profiles. A 'hold' recommendation is appropriate to observe initial sales performance, reimbursement uptake, and how the company addresses its funding needs and manages the safety profile in a real-world setting before making a more definitive 'buy' or 'sell' decision.

Keywords

LYMPHIR, denileukin diftitox-cxdl, CTCL, Cutaneous T-cell Lymphoma, Oncology, Biopharmaceutical, FDA Approved, Cancer Immunotherapy, IL-2 Receptor, Orphan Drug, CTOR, Citius Oncology